Vital Therapies reported $87.18M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Biomarin Pharmaceutical BMRN:US $ 641.53M 25.78M
Dynavax Technologies DVAX:US $ 129.61M 50.55M
Enanta Pharmaceuticals ENTA:US $ 4.6M 72.53M
Epizyme EPZM:US $ 80.16M 6.45M
Insmed INSM:US $ 928.33M 518.58M
Intercept Pharmaceuticals ICPT:US $ 145.62M 52.67M
Mirati Therapeutics MRTX:US $ 258.99M 35.9M
Omeros OMER:US $ 12.7M 3.67M
Orasure Technologies OSUR:US $ 158.12M 19.56M
Quidel QDEL:US $ 593.22M 387.83M
Regulus Therapeutics RGLS:US $ 41.44M 9.84M
Revance Therapeutics RVNC:US $ 167.63M 81.79M
Ultragenyx Pharmaceutical RARE:US $ 290.88M 92.92M
United Therapeutics UTHR:US $ 942.2M 109.9M
Vital Therapies VTL:US $ 87.18M 27.66M